| 10.94 -1.14 (-9.44%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.26 |
1-year : | 15.21 |
| Resists | First : | 12.21 |
Second : | 13.02 |
| Pivot price | 12.3 |
|||
| Supports | First : | 10.89 |
Second : | 9.06 |
| MAs | MA(5) : | 12 |
MA(20) : | 12.22 |
| MA(100) : | 13.36 |
MA(250) : | 12.8 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.9 |
D(3) : | 47.8 |
| RSI | RSI(14): 29.7 |
|||
| 52-week | High : | 19.67 | Low : | 9.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EMBC ] has closed below the lower bollinger band by 16.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ EMBC ] is to continue within current trading range. Bollinger Bands are 17.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.1 - 12.17 | 12.17 - 12.24 |
| Low: | 10.72 - 10.79 | 10.79 - 10.87 |
| Close: | 10.81 - 10.93 | 10.93 - 11.06 |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Fri, 23 Jan 2026
Embecta (NASDAQ:EMBC) Stock Price Down 6.3% - Should You Sell? - MarketBeat
Fri, 23 Jan 2026
embecta to Report Fiscal First Quarter Financial Results - Sahm
Thu, 22 Jan 2026
Embecta Corp. to Host Conference Call for Fiscal Q1 2026 Financial Results and Operational Update - Quiver Quantitative
Tue, 13 Jan 2026
Embecta Corp. $EMBC Shares Sold by State of Alaska Department of Revenue - MarketBeat
Fri, 09 Jan 2026
Embecta Corp. (EMBC): Investor Outlook Reveals 30.62% Potential Upside Amidst Mixed Ratings - DirectorsTalk Interviews
Fri, 09 Jan 2026
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 59 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 99.9 (%) |
| Shares Short | 3,620 (K) |
| Shares Short P.Month | 3,190 (K) |
| EPS | 1.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -11.12 |
| Profit Margin | 8.8 % |
| Operating Margin | 24.8 % |
| Return on Assets (ttm) | 16.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -7.7 % |
| Gross Profit (p.s.) | 11.54 |
| Sales Per Share | 18.24 |
| EBITDA (p.s.) | 6.01 |
| Qtrly Earnings Growth | 82.6 % |
| Operating Cash Flow | 192 (M) |
| Levered Free Cash Flow | 183 (M) |
| PE Ratio | 6.75 |
| PEG Ratio | 0 |
| Price to Book value | -0.99 |
| Price to Sales | 0.59 |
| Price to Cash Flow | 3.37 |
| Dividend | 0.15 |
| Forward Dividend | 0 |
| Dividend Yield | 1.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|